Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharma leader in AL Amyloidosis therapies, announced participation in Morgan Stanley's Global Healthcare Conference. The company will conduct one-on-one investor meetings and provide updates on its lead CAR-T cell therapy candidate, NXC-201, which has received FDA Breakthrough Therapy, RMAT,…